Lv1
98 积分 2023-09-22 加入
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
2小时前
已完结
Long-Term Stabilization of Maleimide–Thiol Conjugates
2小时前
已完结
Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design
2小时前
已完结
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
2小时前
已完结
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
2小时前
已完结
Cathepsin B: Multiple roles in cancer
8天前
已完结
Minimising the payload solvent exposed hydrophobic surface area optimises the antibody-drug conjugate properties
24天前
已完结
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
1个月前
已完结
Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease
1个月前
已完结
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader
1个月前
已完结
皖公网安备34019202002308
